Pharma firms pile up add-on patents to keep drug prices high
Add-on patents have extended drug patent periods from two years to over six, helping pharmaceutical companies maintain high prices.
Headline and summary written by an AI model from the linked article; not reviewed by a person. How this was made
This story has stopped developing; this page is its permanent record. More from that day
The story so far
1 publisher has covered this in 1 article since 28 Sept 2026. Ars Technica published first, on 28 September at 19:53 UTC.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
Sources
Every article we clustered into this story. Headlines link to the publisher.